{
    "clinical_study": {
        "@rank": "166642", 
        "acronym": "Ketamine", 
        "arm_group": {
            "arm_group_label": "Ketamine infusion", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "Study hypothesis: Do serial low-dose ketamine infusions, followed by weekly maintenance\n      infusions, increase the length of time depressive symptoms stay in remission and the length\n      of time associated suicide risk is improved?\n\n      Brief Summary: This open label clinical trial is intended to further clarify initial\n      response to low-dose ketamine infusion with repeated dosing and maintenance treatment model.\n       Primary outcomes will be reduction in depression severity and reduction of suicide risk\n      along with duration of response."
        }, 
        "brief_title": "Ketamine for Depression and Suicide Risk", 
        "completion_date": {
            "#text": "May 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Depression", 
            "Suicide"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Depression", 
                "Depressive Disorder", 
                "Suicide"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Ability to provide informed consent\n\n          -  Current psychiatric inpatient at time of initiation of treatment.\n\n          -  Male/Female\n\n          -  Age 18-65 yrs.\n\n          -  Depressive episode (unipolar or bipolar I or II) with Patient Health Questionnaire-9\n             score >20 at initial hospital assessment\n\n          -  Treatment resistant depression as defined by at least two previous trials of\n             antidepressants in adequate dose for 8 weeks\n\n          -  Patient reported overall suicide risk score \u22653 on the Suicide Status Form or score of\n             3 on Item 9 of Patient Health Questionnaire-9 at admission assessment\n\n          -  Ability to pass comprehension assessment test related to effects of ketamine and\n             trial objectives and criteria\n\n          -  Voluntary admission\n\n        Exclusion Criteria:\n\n          -  Diagnosis of schizophrenia, schizoaffective disorder, or active psychosis\n\n          -  Index episode of depression greater than 2 years\n\n          -  Currently using Gabapentin, Pregabalin, or Valproate or having used within 4 days\n\n          -  Ongoing prescription of \u22654 mg lorazepam equivalents total daily or a.m. dosing of any\n             benzodiazepine at time of assessment\n\n          -  Currently undergoing electroconvulsive therapy, deep brain stimulation or\n             transcranial magnetic stimulation as acute series or for maintenance\n\n          -  Any active or unstable medical condition as judged by principal investigator\n\n          -  Previous use or abuse of methamphetamine, cocaine, stimulants (prescribed and\n             illicit) within past 12 months\n\n          -  Any current abuse or dependence of alcohol or drugs (except nicotine) and abuse or\n             dependence of drugs and alcohol only in full remission (> 1 month, < 12 months).\n             Patients will be allowed to enroll if their drug and alcohol abuse / dependence is in\n             full (complete, not partial) sustained (> 1 year) remission.\n\n          -  History of traumatic brain injury\n\n          -  Developmental delay and intellectual disorder\n\n          -  Encephalopathy (clinical diagnosis within prior 12 months of delirium)\n\n          -  Cognitive disorder (mild and major)\n\n          -  Previous participation in earlier Ketamine trial\n\n          -  Pregnancy\n\n          -  Prisoners\n\n          -  Involuntarily hospitalized"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 10, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02094898", 
            "org_study_id": "13-005152"
        }, 
        "intervention": {
            "arm_group_label": "Ketamine infusion", 
            "description": "0.5 mg/kg of ketamine infused over 100 minutes", 
            "intervention_name": "Ketamine", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Ketamine"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Depression", 
            "Unipolar", 
            "Bipolar", 
            "Suicidal"
        ], 
        "lastchanged_date": "March 20, 2014", 
        "location": {
            "contact": {
                "last_name": "Timothy W Lineberry, MD"
            }, 
            "facility": {
                "address": {
                    "city": "Rochester", 
                    "country": "United States", 
                    "state": "Minnesota", 
                    "zip": "55905"
                }, 
                "name": "Mayo Clinic"
            }, 
            "investigator": {
                "last_name": "Timothy W Lineberry, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Acute and Maintenance Intravenous Ketamine for Treatment Resistant Major Depression With Suicidal Ideation/Attempt", 
        "overall_contact": {
            "email": "Lineberry.Timothy@mayo.edu", 
            "last_name": "Timothy W Lineberrry, MD", 
            "phone": "(507) 284-3352"
        }, 
        "overall_official": {
            "affiliation": "Consultant - Psychiatry", 
            "last_name": "Timothy W Lineberry, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The primary outcome will be remission as defined by a Montgomery Asberg Depression Scale (MADRS) score </=9", 
            "measure": "Improvement in depressive symptoms", 
            "safety_issue": "Yes", 
            "time_frame": "Measured at baseline, with each treatment (up to 3 times weekly) acutely, and then weekly with maintenance treatment (4 weeks), then once weekly with follow up after treatment ends for four weeks."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02094898"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Mayo Clinic", 
            "investigator_full_name": "Timothy W. Lineberry, M.D.", 
            "investigator_title": "Consultant - Psychiatry", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "The secondary outcome measures include reduction of suicidality as defined by a reduction in the Suicide Status Form (SSF II-R) score and suicide assessment of MADRS along wit self-report remission of symptoms as defined by a Quick Inventory of Depressive Symptomatology Self-Report of </=5.", 
            "measure": "Reduction of suicide risk", 
            "safety_issue": "Yes", 
            "time_frame": "Measured at baseline, with each treatment (up to 3 times weekly) acutely, and then weekly with maintenance treatment (4 weeks), then once weekly with follow up after treatment ends for four weeks."
        }, 
        "source": "Mayo Clinic", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Mayo Clinic", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}